OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+59.01%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$823M
AUM Growth
+$823M
(+32%)
Cap. Flow
+$45.5M
Cap. Flow
% of AUM
5.53%
Top 10 Holdings %
Top 10 Hldgs %
56.24%
Holding
65
New
32
Increased
8
Reduced
3
Closed
9
Top Buys
| 1 |
ArriVent BioPharma
AVBP
|
$34.7M |
| 2 |
Dianthus Therapeutics
DNTH
|
$24.8M |
| 3 |
EyePoint Pharmaceuticals
EYPT
|
$22.6M |
| 4 |
Ocular Therapeutix
OCUL
|
$22.1M |
| 5 |
MindMed
MNMD
|
$20.2M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$116M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$63.2M |
| 3 |
Arcus Biosciences
RCUS
|
$35.7M |
| 4 |
Celldex Therapeutics
CLDX
|
$28.1M |
| 5 |
Roivant Sciences
ROIV
|
$28M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $165M | 19.77% | 2,806,980 | – | – |
|
|
ALPN
2
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $49.2M | 5.9% | 1,241,300 | – | – |
|
|
3
Dianthus Therapeutics
DNTH
$759M
| $41.4M | 4.96% | 1,380,667 +826,667 | +149% | +$24.8M |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $38.1M | 4.57% | 2,369,000 | – | – |
|
5
Dyne Therapeutics
DYN
$1.92B
| $35.3M | 4.23% | 1,242,945 +450,000 | +57% | +$12.8M |
|
|
6
ArriVent BioPharma
AVBP
$776M
| $34.7M | 4.16% | +1,943,836 | New | +$34.7M |
|
7
Insmed
INSM
$28.8B
| $30.9M | 3.71% | 1,140,000 -144,000 | -11% | -$3.91M |
|
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.25B
| $23.3M | 2.79% | 2,060,100 | – | – |
|
|
9
EyePoint Pharmaceuticals
EYPT
$797M
| $22.6M | 2.71% | +1,093,503 | New | +$22.6M |
|
|
10
Ocular Therapeutix
OCUL
$2.12B
| $22.1M | 2.64% | +2,425,000 | New | +$22.1M |
|
11
Structure Therapeutics
GPCR
$1.11B
| $21.7M | 2.6% | 506,604 +92,604 | +22% | +$3.97M |
|
12
BridgeBio Pharma
BBIO
$9.89B
| $21.3M | 2.56% | 690,000 -16,800 | -2% | -$519K |
|
|
13
MindMed
MNMD
$676M
| $20.2M | 2.43% | +2,153,000 | New | +$20.2M |
|
14
Perspective Therapeutics
CATX
$250M
| $17.5M | 2.1% | +14,718,422 | New | +$17.5M |
|
15
Corbus Pharmaceuticals
CRBP
$115M
| $15.9M | 1.9% | +405,000 | New | +$15.9M |
|
16
Praxis Precision Medicines
PRAX
$958M
| $15.9M | 1.9% | +260,000 | New | +$15.9M |
|
17
Tenaya Therapeutics
TNYA
$184M
| $14.9M | 1.79% | +2,854,000 | New | +$14.9M |
|
|
18
Jasper Therapeutics
JSPR
$45.5M
| $14.7M | 1.76% | 500,811 -3,967,303 | -89% | -$116M |
|
19
Annexon
ANNX
$226M
| $14.7M | 1.76% | 2,050,000 | – | – |
|
20
Cytokinetics
CYTK
$4.23B
| $13.6M | 1.63% | 194,000 +78,000 | +67% | +$5.47M |
|
|
JBIO
21
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $11.9M | 1.43% | 403,685 | – | – |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $10.9M | 1.3% | 620,000 | – | – |
|
23
Gossamer Bio
GOSS
$562M
| $10.8M | 1.3% | 9,187,883 | – | – |
|
24
NewAmsterdam Pharma
NAMS
$2.71B
| $9.65M | 1.16% | +408,000 | New | +$9.65M |
|
|
CBIO
25
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $9M | 1.08% | 3,000,000 | – | – |
|